.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Business PracticeSee All >

Business
Development
Legal
Policy
Practice
Regulatory

About
Contact
Advisory Board
Do Not Sell My Information
Terms & Conditions
Privacy Policy

Understanding and Improving Access of Biosimilars in Oncology

EP. 1: Biosimilars in Oncology: Addressing Awareness

May 29th 2020

EP. 2: Current State of Biosimilars: Approval, Availability, and Efficacy

May 29th 2020

EP. 3: Biosimilars in Oncology: Equivalency and Cost

May 29th 2020

EP. 4: Are Biosimilar Costs a Factor for Patients?

May 29th 2020

EP. 5: Biosimilars: Addressing Roadblocks to Market Adoption

May 29th 2020

EP. 6: Switching to Available Biosimilars in Oncology

May 29th 2020

EP. 7: Determining Biosimilars' Role in the Formulary

May 29th 2020

EP. 8: Market-Access Considerations for Biosimilars in Oncology

May 29th 2020

EP. 9: Where Do Biosimilars Fit in to the Treatment Landscape?

May 29th 2020

EP. 10: Multiple Biosimilars for a Single-Reference Biologic

May 29th 2020